- Published at
- by gurufocus.com
positive
positive
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting | TGTX Stock News
BRIUMVI's 600 mg single dose effectively tolerated, streamlining dosing potential. Long-term data from ULTIMATE I and II affirms sustained efficacy in M